Molecular Pharmaceutics · 2024 · 11 citations · 34 references
PharmacyPharmaceuticsPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineDrug EncapsulationNanocarriers For TherapeuticsNanomedicineNanoparticle DesignNanoparticle FormulationsAmphiphilic Self-assemblyChemotherapy DeliveryDrug Delivery NanocarriersMicelle Drug DeliveryMicellesNeurotoxicityPolymer MicellesPolymeric Micelles
Paclitaxel (PTX) is one of the first-line drugs for prostate cancer (PC) treatment. However, the poor water solubility, inadequate specific targeting ability, multidrug resistance, and severe neurotoxicity are far from being fully resolved, despite diverse PTX formulations in the market, such as the gold-standard PTX albumin nanoparticle (Abraxane) and polymer micelles (Genexol-PM). Some studies attempting to solve the multiple problems of chemotherapy delivery fall into the trap of an extremely complicated formulation design and sacrifice druggability. To better address these issues, this study designed an efficient, toxicity-reduced paclitaxel-ginsenoside polymeric micelle (RPM). With the aid of the inherent amphiphilic molecular structure and pharmacological effects of ginsenoside Rg5, the prepared RPM enhances the water solubility and active targeting of PTX, inhibiting chemotherapy resistance in cancer cells. Moreover, the polymeric micelles demonstrated favorable anti-inflammatory and neuroprotective effects, providing ideas for the development of new clinical anti-PC preparations.
34
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Development and testing of a general amber force field
Junmei Wang, Romain M. Wolf, James W. Caldwell et al. · Journal of Computational Chemistry · 2004 · 19.6K citations
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver · Molecular Biology of the Cell · 2014 · 1.6K citations
Medicine, Oncology, Pharmacology +13